Alberta Adds ELIDEL® Cream to Public Drug Plan for Atopic Dermatitis
Event summary
- Alberta's public drug plan now covers ELIDEL® (pimecrolimus) cream for eligible patients with mild to moderate atopic dermatitis.
- The addition expands reimbursement coverage, following existing listings in British Columbia, Saskatchewan, Ontario, and Québec.
- ELIDEL® has been available by prescription in Canada since 2003 and is indicated as a second-line therapy for atopic dermatitis.
- Clinical trials show ELIDEL® significantly improves symptoms compared to vehicle treatments.
The big picture
Bausch Health's inclusion of ELIDEL® in Alberta's public drug plan broadens access to a non-corticosteroid treatment for atopic dermatitis, aligning with trends toward expanded coverage for dermatological therapies. This strategic move could enhance patient outcomes and strengthen Bausch Health's position in the Canadian dermatology market.
What we're watching
- Market Expansion
- Whether Bausch Health can leverage this reimbursement to drive further adoption in other provinces.
- Competitive Dynamics
- How this move affects competitors offering similar treatments for atopic dermatitis.
- Regulatory Impact
- The pace at which other regions may follow Alberta's lead in covering ELIDEL® under public drug plans.
Related topics